SC
XLO icon

Stempoint Capital’s Xilio Therapeutics XLO Stock Holding History

Stempoint Capital’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-145,002
Closed -$1.3M – 118
2025
Q4 		$1.3M Buy
+145,002
New +$1.52M 0.22% 64

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stempoint Capital's XLO Position: Q1 2026 in Review

Stempoint Capital sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 145,002 shares — an estimated $1.3M sold.

Stempoint Capital first reported a position in XLO in Q4 2025 and held it in 1 quarter. The position peaked at $1.3M in Q4 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Stempoint Capital reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 145,002 Xilio Therapeutics shares in Q1 2026, an estimated $1.3M.
  • Stempoint Capital first reported a position in Xilio Therapeutics in Q4 2025 and held it in 1 quarter.
  • Stempoint Capital's Xilio Therapeutics position peaked at $1.3M in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.